Generic Name and Formulations:
Tamsulosin HCl 0.4mg; caps.
Boehringer Ingelheim Pharmaceuticals
Indications for FLOMAX:
Swallow whole. Take ½ hr after same meal of each day. Initially 0.4mg once daily; may increase to 0.8mg once daily after 2–4 weeks if response is inadequate. If therapy is interrupted, resume at 0.4mg once daily and retitrate.
Rule out prostate cancer. Sulfa allergy. Syncope. End-stage renal disease. Cataract or glaucoma surgery: do not initiate therapy (possible Intraoperative Floppy Iris Syndrome). Pregnancy (Cat.B).
Do not use with other α-blockers or strong CYP3A4 inhibitors (eg, ketoconazole). Caution with concomitant moderate CYP3A4 inhibitors (eg, erythromycin), moderate or strong CYP2D6 inhibitors (eg, paroxetine, terbinafine), or CYP2D6 poor metabolizers (esp. with tamsulosin >0.4mg/day). Caution with concomitant cimetidine (esp. with tamsulosin >0.4mg/day) or warfarin. Symptomatic hypotension with concomitant PDE5 inhibitors.
Headache, abnormal ejaculation, dizziness, rhinitis, infection, asthenia, back pain, diarrhea, pharyngitis, chest pain, nausea, tooth disorder, blurred vision, cough, somnolence, sinusitis, libido decreased, insomnia; rare: priapism.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D